Liver Transplantation With Two-stage Liver Resection in Unresectable Liver Cancer , Metastases or Emd-stage Liver Disease (LTLR-LC)

Launched by RENJI HOSPITAL · Feb 19, 2023

Keywords

ClinConnect Summary

This clinical trial, called LTLR-LC, is investigating a new treatment approach for patients with severe liver problems due to unresectable primary liver cancer, colon cancer that has spread to the liver, or end-stage liver disease. Traditional liver transplantation can be challenging due to a shortage of available donor livers. This trial aims to explore a surgical method that combines liver removal and transplantation in two stages, which may help patients who currently have few options for treatment.

To participate in this study, individuals must be between 18 and 75 years old and have specific conditions such as unresectable liver cancer that has not worsened after chemotherapy, or end-stage liver disease. Participants will undergo a thorough assessment to ensure they can handle the surgery, and they must be willing to sign a consent form to join the trial. While the study is not yet recruiting participants, those who qualify can expect to receive care from experienced medical teams and contribute to valuable research that could improve treatment for liver diseases in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. aged 18-75 years;
• • 2. patients with unresectable primary hepatocellular carcinoma or colorectal cancer with liver metastases who also meet the following criteria: tumor shrinkage (still unresectable) or no significant progression after a first-line chemotherapy regimen of 6-8 weeks; no other abdominal metastases or 1-3 resectable pulmonary metastases;
• • 3. patients with end-stage liver disease;
• • 4. preoperative Child classification of A or B, able to tolerate the subsequent surgical program
• • 5. Signed informed consent Note: One of the second or third criteria needs to be fulfilled and all the rest of the selection criteria need to be fulfilled
• Exclusion Criteria:
• • 1. Extrahepatic tumor burden (except for resectable lung metastases) and/or macrovascular tumor infiltration
• • 2. Tumor progression during chemotherapy or important comorbidities that affect surgery
• • 3. Uncorrectable cardiopulmonary disease with high surgical risk
• • 4. Anatomical abnormalities that preclude liver transplantation
• • 5. Persistent non-compliance with medical care
• • 6. Combined with other diseases such as AIDS that affect surgery or tumor progression